ma 07 sept - Market First @ UBS Acacias Genève
5th Bio Tuesday of 2004:
A distinguished panel of experts representing a broad range of stakeholders
involved in the screening, assessment and valuation of Life Sciences opportunities
will explain the art and science of evaluating opportunities. Companies
that sell products or services on a market can be evaluated and valued based
on a number of parameters, based on their revenues and projected cash flows.
But how do you valuate an idea? How does a technology transfer office place
a value on an invention coming out of academia? How does an incubator decide
which start-up companies to support? How does a Venture Capitalist assess
the possible future value of an investment in an emerging biotech company?
How does an established bio-pharma company assess the value of a product
it wishes to in-license or a candidate company it is thinking of acquiring
or merging with? How do investment bankers or market analysts set a share
price for an unproven biotech or medical device company that only has a
few young products in its pipeline?
Although many methodologies exist to assess opportunities, the risk/reward
profile of each opportunity in the Life Sciences requires different investment
metrics, depending on the profession of the evaluator and the stage of
the opportunity.
Panel in English. Tous les intervenants parleront en anglais.
- 16h30 Welcome
- 17h00 Conference
- 19h00 Networking
Main auditorium @ UBS Acacias Geneva
Rue des Noirettes 35, Geneva
PARKING UBS free from 5 pm
Panel
Organised, introduced and moderated by Jeremy Lack, Medabiotech
SA with
With
- ((( Alexandra Richardson and Raluca Flukiger,
Unitec Life Sciences
Group, the University of Geneva’s Technology Transfer Office How opportunities
are sourced and supported by the University’s tech transfer department,
what metrics they use when selecting a technology to be protected.
- ((( Jesus Martin-Garcia, Director, Eclosion,
Geneva’s Life Science Incubator. The Canton has recently approved
the financing of an incubator dedicated to supporting the creation of
Life Science start-ups in our region. Its co-founder and Director will
give us a brief overview of this new structure, and how it selects and
values the companies it supports.
- ((( Andreas Wicki, Director & CEO, HBM
Bio Ventures HBM Bio Ventures is one of Europe’s leading investors
in the Life Sciences. Dr Wicki, its Director and CEO, will present how
Private Equity funds assess and valuate investment opportunities, and
how valuation analysis, in the public and private equity markets may differ.
- ((( Subhasis Roy, Corporate Finance Group, UBS
Investment Bank Finally, after a Life Sciences start-up company has
been launched, nurtured, and matured, it is ready for the public markets.
UBS will explain the methodologies it uses when selecting and evaluating
companies preparing for an Initial Public Offering and how analysts set
and keep track of the share price of a company that wishes to float on
a public stock market.
Elevator Pitch
- ((( François Delaite,
Société Privée de Gérance Vous êtes actifs dans les BIOTECH et les NTIC.
Vous cherchez une implantation idéale à Genève proche du centre ville,
à quelques minutes de la gare et de l’aéroport, dotée de toutes les
commodités et qui assure à votre société une visibilité alliant design,
prestige et high-tech. Nous avons la solution: LE CHARMILLES NEW TECH
CENTER vous offre aujourd’hui la modularité que vous cherchez: de 200
à 13’000m2 aménageables au grès du preneur.
Free admission, but registration mandatory
by clicking on
[Je m'inscris], here above
About Bio Tuesday
Bio Tuesday events are an initiative that started in 2000 in Suisse Romande
as a collaboration between Genevieve Morand of Rezonance and Jeremy Lack
of Medabiotech to heighten public awareness of biotechnology and the importance
of Switzerland's pharma and emerging Life Sciences industry. The concept
has now been introduced in Zurich as well. We promote entrepreneurship
and encourage the creation of new start-up companies in our region, which
has one of the high concentrations of talent in the Life Sciences in Europe.
Bio Tuesday events are free and open to the general public and attract
a broad audience (min 200 - max to date of 660 attendees) from all sectors
of the local community, including: investors, start-ups, multinationals,
government officials, entrepreneurs, academics, lawyers, journalists,
business angels, bankers etc. Information about our events can be found
on the internet on Rezonance. These events allow people interested in
the Life Sciences in Switzerland to meet several times a year and to network
around high-quality events that address themes of common interest or concern.
Should you be interested in knowing more about these events, speaking
at one of them, or becoming a Bio Tuesday sponsor, please contact Genevieve
Morand.
FORWARD
This event is free and open to all. You are welcome to forward this invitation to anyone you
know who may be interested in this event.
Thank you for your continued interest and support in
these events. We look forward to seeing you on September 7th
Best regards,
((( Jeremy Lack
Director & General Counsel Medabiotech SA
Counsel to Etude Ziegler, Poncet & Grumbach
((( Geneviève Morand, CEO
Rezonance.ch, People, Knowledge & Business Network
Membre du réseau First Tuesday
Rezonance.ch - septembre 2004
